EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

M.D.P. BRICEÑO CASADO1, M.D. GIL-SIERRA2, B. DE LA CALLE RIAGUAS1, M. DOMINGUEZ-CANTERO3.
1HOSPITAL NUESTRA SEÑORA DEL PRADO, HOSPITAL PHARMACY, TALAVERA DE LA REINA, SPAIN. 2HOSPITAL DOCTOR JOSE MOLINA OROSA, HOSPITAL PHARMACY, LANZAROTE, SPAIN. 3HOSPITAL UNIVERSITARIO PUERTO REAL, HOSPITAL PHARMACY, CADIZ, SPAIN.

BACKGROUND AND IMPORTANCE
Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. It is used for treatment of moderate-to-severe plaque psoriasis (MTSPP).

AIM AND OBJECTIVES
To assess effectiveness and safety of ixekizumab in MTSSP in clinical practice.

MATERIAL AND METHODS
➢ Descriptive retrospective multicenter study was conducted.
➢ Patients with MTSPP receiving ixekizumab between 01/01/2017-30/09/2020 were included.
➢ Electronic clinical history and prescription program Farmatools® were used to record data: sex, age, previous treatment, dosage and duration of therapy.
➢ Effectiveness → measured by Psoriasis Area Severity Index (PASI): PASI-75 (≥75% reduction in baseline PASI), PASI-90 (≥90% reduction) and PASI-100 (total clearance of lesions) at weeks 12 and 36. Failure to achieve PASI-75 was considered as no response.
➢ Safety → evaluated according to adverse events (AE) and discontinuations of treatment.

RESULTS
➢ 46 patients: 27 (59%) men. Mean age = 49 (23-74) years.
➢ Induction dose: 160 mg at week 0, then 80 mg at weeks 2, 4, 6, 8, 10 and 12. Maintenance: 80 mg every 4 weeks in 34 (74%) patients and every 6 weeks in 12 (26%).
➢ Baseline PASI >5 in all patients and >10 in 37 (80%) cases.
➢ Mean duration therapy = 17 (3-44) months.

PREVIOUS TREATMENT:
methotrexate (n=33), cyclosporine (n=29) and biological therapy (n=35).
Mean of prior biological drugs was 3 (1-5), including:
• anti-TNF (etanercept, n=23; adalimumab, n=22; infliximab, n=3)
• anti-IL12-23 (ustekinumab, n=16)
• anti-IL17A (secukinumab, n=7)

EFFECTIVENESS → not evaluated in 5 (11%) patients at week 12 and 8 (17%) at week 36 due to lack of information.
➢ At week 12: one (2%) patient presented PASI-75, 12(26%) PASI-90, 23 (50%) PASI-100 and 5 (11%) no response.
➢ At week 36: one (2%) patient achieved PASI-75, 15 (33%) PASI-90, 16 (35%) PASI-100 and 6 (13%) no response.

SAFETY PROFILE → 3 (7%) patients presented AE: alopecia, eosinophilia and injection site reaction. No discontinuations of treatment were reported.

CONCLUSION AND RELEVANCE
Ixekizumab was effective and provided a total clearance of MTSSP lesions to half of patients at week 12, showing this considerable response in more than a third of patients at week 36. Ixekizumab was well tolerated, with low frequency of AE.